Novel cell culture model for prevention of carcinogenic risk in familial adenomatous polyposis syndrome

Oncology Reports

Volumn 21, Issue 4, 2009, Pages 1017-1021

  Telang, Nitin ^a   Katdare, Meena ^b  

^a Palindrome Liaisons   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Apc mutation; Carcinogenic risk; Chemoprevention; Colon epithelial cells

Indexed keywords

DEXAMETHASONE; EFLORNITHINE; EPIGALLOCATECHIN GALLATE; ICOSAPENTAENOIC ACID; SULINDAC; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; ANTINEOPLASTIC AGENT; CATECHIN; DRUG DERIVATIVE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER INVASION; CANCER RISK; CANCER SUSCEPTIBILITY; CELL CULTURE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL GROWTH; COLON CANCER; COLON POLYPOSIS; CONTROLLED STUDY; DRUG MECHANISM; GROWTH INHIBITION; HIGH RISK PATIENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; ANIMAL; C57BL MOUSE; CELL LINE; COLON TUMOR; GENETICS; MUTATION; PATHOLOGY; TUMOR SUPPRESSOR GENE;

ADENOMATOUS POLYPOSIS COLI; ANIMALS; ANTICARCINOGENIC AGENTS; CATECHIN; CELL LINE; COLONIC NEOPLASMS; EFLORNITHINE; EICOSAPENTAENOIC ACID; GENES, APC; MICE; MICE, INBRED C57BL; MUTATION;

EID: 67449102998     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000318     Document Type: Article

References (37)

1. Jemal AR, Segal R, Ward E, et al: Cancer statistics. Cancer J Clin 58: 71-96, 2008.
2. Kelloff GJ, Lippman SM, Dannenberg AJ, et al: Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer, a plan to move forward. Clin Cancer Res 22: 3661-3697, 2006.
3. O'Shauhnessy JA, Kelloff GJ, Gordon GB, et al: Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 8: 314-346, 2002.
4. Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990.
5. Hong WK and Sporn MB: Advances in chemoprevention of cancer. Science 278: 1073-1077, 1997.
6. Min mouse model of familial adenomatous polyposis. Cancer Res 60: 5040-5044, 2000.
7. Jacoby RF, Cole CE, Tutsch K, et al: Chemopreventive efficacy of combined Piroxicam and Difluoro methylornithine treatment on Apc mutant mouse adenoma and selective toxicity against Apc mutant embryos. Cancer Res 60: 1864-1870, 2000.
8. Min mice. Cancer Res 66: 7370-7377, 2006.
9. Torrance CJ, Jackson PE, Montgomery E, et al: Combinatorial chemoprevention of intestinal neoplasia. Nat Med 6: 1024-1028, 2000.
10. Fodde R, Smits R and Clevers H: Apc signal transduction and genetic instability in colon cancer. Nat Rev Cancer 1: 55-67, 2001.
11. Moser AR, Pitot HC and Dove WF: A dominant mutation that predisposes to multiple intestinal neoplasia in mouse. Science 247: 322-324, 1990.
12. Su L-K, Kinzler KW, Vogelstein B, et al: Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256: 668-670, 1992.
13. Katdare M, Kopelovich L and Telang N: Efficacy of chemopreventive agents on growth inhibition of Apc [+/-] 1638NCOL colonic epithelial cells. Int J Mol Med 10: 427-432, 2002.
14. Telang N and Katdare M: Combinatorial prevention of carcinogenic risk in a model for familial colon cancer. Oncol Rep 17: 909-914, 2007.
15. Telang NT, Li G and Katdare M: Prevention of early onset familial/ hereditary colon cancer: new models and mechanistic biomarkers (Review). Int J Oncol 28: 1523-1529, 2006.
16. Telang NT, Osborne MP, Sweterlitsch LA, et al: Neoplastic transformation of mouse mammary epithelial cells by deregulated myc expression. Cell Regulation 1: 863-872, 1990.
17. Min/+ compound mutant mice is linked to premature separation of sister chromatid and enhanced genomic instability. Proc Natl Acad Sci USA 102: 4365-4370, 2005.
18. Min/+ mice. Cancer Res 66: 8430-8438, 2006.
19. Cho NL, Javid SH, Carothers AM, et al: Estrogen receptors α and β are inhibitory modifiers of Apc dependent tumorigenesis in the proximal colon of Min/+ mice. Cancer Res 67: 2366-2372, 2007.
20. Fijneman R, De Wit H, Pourghiasian M, et al: Identification of mouse colon tumor secretome as putatyive biomarker for blood-based screening of colorectal cancer. Cell Oncol 30: 156, 2008.
21. Yang K, Popova NV, Yang WC, et al: Interaction of Muc2 and Apc on wnt signaling and intestinal tumorigenesis: potential role of chronic inflammation. Cancer Res 68: 7313-7322, 2008.
22. Telang NT, Narayanan R, Bradlow HL, et al: Co-ordinated expression of intermediate biomarkers for tumorigenic transformation of Ras transfected mouse mammary epithelial cells. Breast Cancer Res Treat 18: 155-163, 1991.
23. Telang N and Katdare M: Cell culture model for colon cancer prevention and therapy: an alternative approach to animal experimentation. ALTEX 24: 16-21, 2007.
24. Massague J, Blain SW and Lo RS: TGF-β signaling in growth control, cancer and heritable disorders. Cell 103: 295-309, 2000.
25. Woodburn JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82: 241-250, 1999.
26. Singh M and Johnson L: Using genetically engineered mouse models of cancer to aid drug development: an industry perspective. Clin Cancer Res 12: 5312-5328, 2006.
27. Frese KK and Tuveson DA: Maximizing mouse cancer models. Nat Rev Cancer 7: 645-658, 2007.
28. Abate-Shen C, Brown PH, Colburn NH, et al: The un-trapped potential of genetically engineered mouse models in chemoprevention research: opportunities and challenges. Cancer Prev Res 1: 161-166, 2008.
29. Bresalier RS, Sandler RS, Quan H, et al: Cardio-vascular events associated with Rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092-1102, 2005.
30. Gerner EW and Meyskens F: Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 4: 785-792, 2004.
31. Giardiello FM, Hamilton SR, Hylind M, et al: Ornithine decarboxylase and polyamines in familial adenomatous polyposis. Cancer Res 57: 199-201, 1997.
32. Solomon SD, McMurray JJV, Pfeffer M, et al: Cardiovascular risk associated with Celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071-1080, 2005.
33. Swamy MV, Cooma I, Jagan MR, et al: Modulation of Cox-2 activity by the combined action of celecoxib and docosa hexaenoic acid: novel strategy for prevention and treatment. Mol Cancer Ther 3: 215-223, 2004.
34. Meyskens FL, McLaren CE, Petot D, et al: Difluoro methylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo controled, double-blind trial. Cancer Prev Res 1: 32-38, 2008.
35. Sarkar FH and Li Y: Using chemopreventive agents to enhance the efficacy of cancer chemotherapy. Cancer Res 66: 3347-3350, 2006.
36. Min/+ mice by (-)-Epigallocatechin-3-gallate, the major catechin in green tea. Cancer Res 65: 10623-10631, 2005.
37. Nagel R, La Sage C, Diosdado B, et al: Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res 68: 5795-5812, 2008.